14.00
3.45%
-0.50
Tyra Biosciences Inc Borsa (TYRA) Ultime notizie
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires New Position in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Wellington Management Group LLP Sells 26,207 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
The Take On Tyra Biosciences (NASDAQ:TYRA) - Seeking Alpha
(TYRA) Trading Signals - Stock Traders Daily
Tyra Biosciences to Present at Upcoming Investor Conferences - The Eastern Progress Online
Charles Schwab Investment Management Inc. Increases Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Frazier Life Sciences Management L.P. Cuts Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) - MarketBeat
Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET - Victoria Advocate
Janus Henderson Group PLC Takes Position in Tyra Biosciences, Inc. (NASDAQ:TYRA) - MarketBeat
Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference - The Eastern Progress Online
Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) - The Eastern Progress Online
(TYRA) Investment Analysis - Stock Traders Daily
Polar Asset Management Partners Inc. Buys New Shares in Tyra Biosciences, Inc. (NASDAQ:TYRA) - MarketBeat
Tyra Biosciences to Participate in 2023 Jefferies London Healthc - GuruFocus.com
Walleye Capital LLC Has $2.98 Million Holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA) - MarketBeat
Sio Capital Management LLC Has $9.42 Million Holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA) - MarketBeat
How to Take Advantage of moves in (TYRA) - Stock Traders Daily
Tyra Biosciences (NASDAQ:TYRA) Stock Price Down 5%Here's Why - MarketBeat
Short Interest in Tyra Biosciences, Inc. (NASDAQ:TYRA) Drops By 20.0% - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Shares Gap UpWhat's Next? - MarketBeat
RA Capital Management, L.P. Increases Stake in Tyra Biosciences Inc - GuruFocus.com
Equities Analysts Offer Predictions for TYRA FY2024 Earnings - MarketBeat
Tyra Biosciences to Present FGFR Precision Medicine Updates at Major Healthcare Conferences - StockTitan
FMR LLC Increases Stake in Tyra Biosciences Inc - GuruFocus.com
Tyra Biosciences stock target cut, retains buy rating on clinical data - Investing.com Canada
HC Wainwright Has Lowered Expectations for Tyra Biosciences (NASDAQ:TYRA) Stock Price - MarketBeat
Tyra Biosciences director Nina Kjellson sells $1.28 million in stock By Investing.com - Investing.com Australia
Tyra Biosciences’ Q3 2024: Clinical Progress and Financial Resilience - TipRanks
Tyra Biosciences director Nina Kjellson sells $1.28 million in stock - Investing.com
Tyra Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights - PR Newswire
Tyra Biosciences director Nina S. Kjellson sells shares worth $194k - Investing.com
Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Sold by Auour Investments LLC - MarketBeat
Long Term Trading Analysis for (TYRA) - Stock Traders Daily
Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up After Insider Buying Activity - MarketBeat
Tyra Biosciences director Nina Kjellson sells $2.28m in stock By Investing.com - Investing.com Australia
Tyra Biosciences director Nina Kjellson sells $2.28m in stock - Investing.com
Tyra Biosciences, Inc. (NASDAQ:TYRA) CFO Purchases $152,000.00 in Stock - MarketBeat
Tyra Biosciences CFO Alan Fuhrman acquires $151,954 in stock By Investing.com - Investing.com South Africa
Tyra Biosciences CFO Alan Fuhrman acquires $151,954 in stock - Investing.com
TYRA-300 shows encouraging safety, efficacy in FGFR3+ metastatic urothelial carcinoma - Urology Times
Tyra Biosciences (NASDAQ:TYRA) Trading Down 10.2%Here's What Happened - MarketBeat
Tyra Biosciences advances with Phase 2 trial for achondroplasia treatment By Investing.com - Investing.com Australia
Tyra Biosciences advances with Phase 2 trial for achondroplasia treatment - Investing.com
Piper Sandler maintains Overweight on Tyra Biosciences stock By Investing.com - Investing.com Canada
Tyra Biosciences stock target lifted, retains buy on clinical trial data - Investing.com Canada
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):